ADAURA
Adjuvant Osimertinib in Resected EGFR-Mutated NSCLC
Patient / Population Intervention / Exposition Comparaison Critère de jugement
In 682 patients with completely resected stage IB–IIIA EGFR-mutated NSCLC, three years of adjuvant osimertinib improved disease-free and overall survival compared with placebo.
N
682
Schéma
Double-blind RCT
Critère
DFS in stage II–IIIA
Pertinence
2
RésultatDFS HR 0.17 (stage II–IIIA). Final OS HR 0.49 (5-yr OS 85% vs 73% in II–IIIA).
Wu YL, et al. N Engl J Med. 2020;383(18):1711-1723; Tsuboi M, et al. N Engl J Med. 2023;389(2):137-147. 10.1056/NEJMoa2027071
Discussion et critique
Established adjuvant osimertinib after resection in EGFR-mutated NSCLC. Optimal duration and stage IB subgroup remain debated.